Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

Background: The presence of infective microorganisms in the bilio-pancreatic tract is believed to be important in both the onset and outcome of acute biliary pancreatitis. In this study ...

Obesity and biliary tract cancers: Changing epidemiology. Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable ...

Efficacy and safety of durvalumab and gemcitabine-based chemotherapy combined with or without lenvatinib in advanced biliary tract cancer. Comparative restricted mean survival time (RMST) analysis of ...

Four-year results of a phase III trial showed that budesonide oral suspension (Eohilia) for eosinophilic esophagitis was well ...

Gallbladder cancer is a highly aggressive condition with vague symptoms, often leading to late diagnosis. Risk factors ...

The following is a summary of “Collagen turnover biomarkers to predict outcome of patients with biliary cancer,” published in ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Beyond improving accuracy, xAI allowed researchers to compare prognostic markers across different cancer types, unveiling ...

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy, the first ...

February is National Cancer Awareness Month, a time to amplify discussions on lesser- known but equally devastating ...